Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2024)
Artiva Biotherapeutics' (ARTV) quarterly Change in Receivables came in at -$569000.0 in Q4 2024, up 48.37% year-on-year from -$383509.5 in Q1 2024, and down 127.6% on a QoQ basis from -$250000.0 in Q2 2024.
Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 2 years of Change in Receivables data on file, last reported at -$569000.0 in Q4 2024.
- On a quarterly basis, Change in Receivables rose 48.37% year-over-year to -$569000.0 in Q4 2024; TTM through Mar 2025 was -$819000.0, a N/A change from a year earlier, with the FY2024 full-year figure at -$1.0 million, down 302.75% from the prior year.
- Change in Receivables for Q4 2024 stood at -$569000.0, down from -$250000.0 in the prior quarter.
- Over the last five years, Change in Receivables for ARTV reached as high as -$80000.0 in Q3 2023 and fell as low as -$1.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -569,000.00 |
| Dec 31, 2024 | -569,000.00 |
| Jun 30, 2024 | -250,000.00 |
| Jun 30, 2024 | -250,000.00 |
| Mar 31, 2024 | -215,000.00 |
| Mar 31, 2024 | -215,000.00 |
| Dec 31, 2023 | -1.10 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -80,000.00 |
| Sep 30, 2023 | -80,000.00 |